Bristol-Myers Squibb to Acquire Celgene Corporation
NEW YORK and SUMMIT, N.J. — In a deal worth $74 billion, Bristol-Myers Squibb announced today its plans to acquire Celgene Corporation. The transaction, according to Bristol-Myers, will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and
